Hong Kong public hospital fee reforms draw complaints over drug charges
Hong Kong's public hospital fee reforms since January have led to complaints about charges for medication without doctor consultations and four-week drug fees. The government defends the changes, citing expanded subsidies and reduced emergency room misuse.
A lawmaker has raised complaints about the Hospital Authority's public healthcare fee reforms, implemented since 1 January, including charges for medication when patients did not see a doctor and fees for a four-week drug supply even if prescribed for less. The government responded in the legislature on 18 November, defending the reforms as a strategic restructuring of subsidies to better protect the poor, critically ill, severely ill and those in emergencies.
The reforms have expanded full medical fee waivers from fewer than 14,000 people annually to over 250,000, with the waiver mechanism covering about HK$900 million in the first ten months of this year. Emergency department attendance for semi-urgent and non-urgent cases fell 7.0 per cent year-on-year, with non-urgent cases dropping 17.5 per cent. Critically ill and emergency patients received full fee exemptions, with the scheme covering about HK$30 million.
A new annual cap of HK$10,000 on fees, without means testing, had been approved for over 24,000 patients by the end of October, exempting about HK$200 million. The government also said 26 new drugs were added to the hospital drug formulary, 13 with government subsidies costing about HK$192 million annually. An additional 31 new drugs or expanded clinical indications and 26 self-funded medical devices were added to the Samaritan Fund, costing over HK$130 million annually.
Regarding the specific complaints, the Hospital Authority said charges for medication without a face-to-face doctor visit were not related to the fee reforms. Under existing arrangements, if patients change or miss appointments and need extra drugs, a doctor must review their medical records and assess their condition before prescribing, which constitutes a consultation fee. Exceptions exist for clinic closures due to bad weather. The authority received no complaints in 2023 and 2024, and one each in 2025 and the first ten months of 2026.
The government noted that since announcing the reforms in March 2025, extensive briefings and training have been provided to legislators, the public, and hospital staff through about 200 sessions including media briefings, patient group meetings, and workshops. On drug fees, the authority reduced the charging unit from 16 weeks to four weeks to better match dispensed quantities, balancing administrative costs and efficiency. The fee structure will be reviewed every two years.